REPLIQA, the Research Program at the Intersection of the Life Sciences and Quantum AI, has launched with the stated aim of applying quantum computing and artificial intelligence to molecular-level problems in human biology and health. The announcement was light on operational detail, offering little beyond the programme's name, mission and a broad statement about the difficulty of modelling biological processes at the molecular scale.
Taken in isolation, the launch reads as aspirational. Taken in the context of what is happening across the quantum biology landscape, it arrives at a moment when the field is beginning to produce results that would have been dismissed as speculative even two years ago.
In January, researchers from IBM, Cleveland Clinic and Japan's RIKEN institute successfully simulated a 12,635-atom protein complex using quantum-centric supercomputing, the largest biological system ever modelled on quantum hardware. The work demonstrated that hybrid quantum-classical approaches can tackle scientifically meaningful problems under real hardware constraints, not just abstract benchmarks.
In April, Finnish quantum software company Algorithmiq became the sole winner of a $2 million Wellcome Leap prize for demonstrating quantum computing's potential to simulate complex drug candidates on systems running up to 100 qubits. The work focused on photodynamic therapy for cancer and produced a scalable framework that the judges said could transfer to wider drug discovery applications.
Venture capital investment in quantum-focused companies reached $3.8 billion in 2025, with another $581 million landing in the first two months of 2026. Major pharmaceutical companies, including Boehringer Ingelheim, Amgen and Novo Nordisk's parent foundation, are building dedicated quantum research capabilities. The Novo Nordisk Foundation pledged $200 million to a quantum computing programme at the University of Copenhagen focused specifically on drug development.
The scientific logic is straightforward. Biological processes, protein folding, molecular interactions, cellular responses to drugs, are governed by quantum mechanics. Classical computers approximate these processes, often well enough for practical purposes but with hard limits on accuracy and scale. Quantum computers, which operate on quantum mechanical principles natively, should in theory simulate molecular behaviour more naturally and accurately. The gap between theory and practice has been the rate-limiting step: quantum hardware has not been powerful enough, or error-free enough, to handle biologically relevant problems.
Related reading
- Nvidia launches open-source quantum AI models as it deepens grip on chip design workflows
- Nvidia quantum AI launch triggers buying frenzy across Asian and US tech stocks
- Nvidia launches Ising AI models to speed quantum processor calibration and error correction
That gap is narrowing. Amgen's head of quantum research estimated that a 1,000-error-free-qubit machine could be available within three to seven years. Nvidia launched its first open-source quantum AI models in April to accelerate quantum error correction, the key technical barrier to reliable computation.
REPLIQA enters a field that is no longer speculative but not yet proven at commercial scale. The programme's value will depend entirely on details it has not yet disclosed: who is behind it, how it is funded, what specific biological problems it intends to address, and whether it brings computational capabilities that advance the state of the art or merely rebrand existing work under a new acronym.
The recap
- REPLIQA launches a program combining quantum science and AI.
- Aims to study human biology at the molecular level.
- Company said it is launching the program in a company blog post.
